...
首页> 外文期刊>Annals of Internal Medicine >Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline
【24h】

Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline

机译:预防成人复发性肾结石的药物治疗:美国医师学院临床指南的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Optimum management to prevent recurrent kidney stones is uncertain. Purpose: To evaluate the benefits and harms of interventions to prevent recurrent kidney stones. Data Sources: MEDLINE, Cochrane, and other databases through September 2012 and reference lists of systematic reviews and ran-domized, controlled trials (RCTs). Study Selection: 28 English-language RCTs that studied treatments to prevent recurrent kidney stones and reported stone outcomes. Data Extraction: One reviewer extracted data, a second checked accuracy, and 2 independently rated quality and graded strength of evidence. Data Synthesis: In patients with 1 past calcium stone, low-strength evidence showed that increased fluid intake halved recurrent com-posite stone risk compared with no treatment (relative risk [RR], 0.45 [95% CI, 0.24 to 0.84]). Low-strength evidence showed that reducing soft-drink consumption decreased recurrent symptomatic stone risk (RR, 0.83 [CI, 0.71 to 0.98]). In patients with multiple past calcium stones, most of whom were receiving increased fluid intake, moderate-strength evidence showed that thiazides (RR, 0.52 [CI, 0.39 to 0.69]), citrates (RR, 0.25 [CI, 0.14 to 0.44]), and allopurinol (RR, 0.59 [CI, 0.42 to 0.84]) each further reduced com-posite stone recurrence risk compared with placebo or control, although the benefit from allopurinol seemed limited to patients with baseline hyperuricemia or hyperuricosuria. Other baseline bio-chemistry measures did not allow prediction of treatment efficacy. Low-strength evidence showed that neither citrate nor allopurinol combined with thiazide was superior to thiazide alone. There were few withdrawals among patients with increased fluid intake, many among those with other dietary interventions and more among those who received thiazide and citrate than among control pa-tients. Reporting of adverse events was poor. Limitations: Most trial participants had idiopathic calcium stones. Nearly all studies reported a composite (including asymptomatic) stone recurrence outcome. Conclusion: In patients with 1 past calcium stone, increased fluid intake reduced recurrence risk. In patients with multiple past cal-cium stones, addition of thiazide, citrate, or allopurinol further re-duced risk. Primary Funding Source: Agency for Healthcare Research and Quality.
机译:背景:预防复发性肾结石的最佳治疗尚不确定。目的:评估预防复发性肾结石的干预措施的利弊。数据来源:截至2012年9月的MEDLINE,Cochrane和其他数据库,以及系统评价和随机对照试验(RCT)的参考清单。研究选择:28种英语RCT,研究了预防肾结石复发的治疗方法并报告了结石结局。数据提取:一位审阅者提取了数据,第二次检查了准确性,并选择了2个独立评估的质量和分级的证据强度。数据综合:过去有1例钙结石的患者,低强度证据表明,与不进行治疗相比,液体摄入量的增加使复发性复合结石的风险减半(相对风险[RR],0.45 [95%CI,0.24至0.84])。低强度证据表明,减少软饮料的摄入量可减少有症状的结石复发风险(RR,0.83 [CI,0.71至0.98])。在过去有多处钙结石的患者中,大多数患者的液体摄入量增加,中等强度的证据显示噻嗪类药物(RR,0.52 [CI,0.39至0.69]),柠檬酸盐(RR,0.25 [CI,0.14至0.44])和别嘌呤醇(RR,0.59 [CI,0.42至0.84])与安慰剂或对照组相比均进一步降低了复合结石复发的风险,尽管别嘌呤醇的益处似乎仅限于基线高尿酸血症或尿酸尿过多的患者。其他基线生化指标无法预测治疗效果。低强度证据表明,柠檬酸盐或别嘌呤醇联合噻嗪均不优于单独的噻嗪。在增加液体摄入量的患者中,撤药的很少,在其他饮食干预中的撤药很多,而接受噻嗪类和柠檬酸盐治疗的患者撤药的比例高于对照组。不良事件的报告很差。局限性:大多数试验参与者患有特发性钙结石。几乎所有研究都报告了复合(包括无症状)结石复发结局。结论:过去有1例钙结石的患者,增加液体摄入量可降低复发风险。对于有多次钙钙结石的患者,添加噻嗪,柠檬酸盐或别嘌呤醇可进一步降低风险。主要资金来源:卫生保健研究与质量局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号